We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+24.5%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$2.32B
AUM Growth
+$320M
Cap. Flow
-$21M
Cap. Flow %
-0.9%
Top 10 Hldgs %
48.35%
Holding
91
New
25
Increased
18
Reduced
19
Closed
23

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$95.5M
2
VERA icon
Vera Therapeutics
VERA
+$82M
3
CLDX icon
Celldex Therapeutics
CLDX
+$53.3M
4
ABVX
Abivax
ABVX
+$39.5M
5
BLTE
Belite Bio
BLTE
+$38.3M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$190M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$84.4M
3
TERN
Terns Pharmaceuticals
TERN
+$79.1M
4
CYTK icon
Cytokinetics
CYTK
+$57.7M
5
UTHR icon
United Therapeutics
UTHR
+$47.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLYS icon
26
Mineralys Therapeutics
MLYS
$2.26B
$28.3M 1.22%
+1,050,000
New +$28.8M
REPL icon
27
Replimune Group
REPL
$1.46B
$27.7M 1.19%
+2,500,000
New +$15.3M
XENE icon
28
Xenon Pharmaceuticals
XENE
$5.81B
$27.2M 1.17%
450,000
– –
GPCR icon
29
Structure Therapeutics
GPCR
$3.38B
$26.8M 1.16%
500,000
– –
IMVT icon
30
Immunovant
IMVT
$8.51B
$25.6M 1.1%
665,000
-410,000
-38% -$12.5M
JBIO
31
Jade Biosciences
JBIO
$1.33B
$25M 1.08%
1,125,000
+725,000
+181% +$15.1M
ELVN icon
32
Enliven Therapeutics
ELVN
$4.24B
$23.6M 1.02%
465,000
-75,000
-14% -$3.18M
MANE
33
Veradermics Inc
MANE
$4.09B
$22.1M 0.95%
180,000
+155,000
+620% +$14.5M
AVTX icon
34
Avalo Therapeutics
AVTX
$1.05B
$21.3M 0.91%
1,150,000
+850,000
+283% +$13.4M
RCUS icon
35
Arcus Biosciences
RCUS
$3.72B
$20M 0.86%
650,000
-550,000
-46% -$13.6M
SMMT icon
36
Summit Therapeutics
SMMT
$11B
$19.7M 0.85%
+1,350,000
New +$23.9M
IMCR icon
37
Immunocore
IMCR
$1.89B
$19.1M 0.82%
600,000
-900,000
-60% -$26.6M
LBRX
38
LB Pharmaceuticals
LBRX
$1.54B
$19M 0.82%
585,000
-330,000
-36% -$9.69M
NERV icon
39
Minerva Neurosciences
NERV
$231M
$18.3M 0.79%
3,288,777
+73,777
+2% +$400K
FTH
40
Faeth Therapeutics
FTH
$874M
$18.1M 0.78%
722,020
+692,020
+2,307% +$16M
CRSP icon
41
CRISPR Therapeutics
CRSP
$5.58B
$16.4M 0.7%
+300,000
New +$15.8M
DBVT
42
DBV Technologies
DBVT
$851M
$15M 0.65%
+915,000
New +$17.3M
PBLS
43
Parabilis Medicines Inc
PBLS
$4.83B
$14.4M 0.62%
+525,000
New +$14.5M
RYTM icon
44
Rhythm Pharmaceuticals
RYTM
$7.38B
$13.9M 0.6%
125,000
-325,000
-72% -$29.4M
VOR icon
45
Vor Biopharma
VOR
$1.34B
$12M 0.52%
650,000
-100,000
-13% -$1.51M
SRRK icon
46
Scholar Rock
SRRK
$7.04B
$11M 0.47%
+200,000
New +$9.66M
IMMX icon
47
Immix Biopharma
IMMX
$992M
$10.3M 0.44%
1,000,000
-225,000
-18% -$2.09M
QTTB icon
48
Q32 Bio
QTTB
$447M
$10.2M 0.44%
+800,000
New +$6.68M
ODTX
49
Odyssey Therapeutics
ODTX
$1.17B
$9.76M 0.42%
+521,736
New +$9.15M
ANNX icon
50
Annexon
ANNX
$942M
$8.56M 0.37%
+1,500,000
New +$8.29M
1
2
3 4

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q2 2026 Portfolio in Review

As of Q2 2026, Logos Global Management held 91 positions worth $2.32B, up 16% from $2B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Logos Global Management's Q2 2026 filing shows 25 new, 18 increased, 19 reduced and 23 closed positions. Its largest new stake was BioNTech: 1,015,000 shares worth $94.4M. The largest sale was Revolution Medicines, an estimated $190M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Financials.

  • Logos Global Management's largest Q2 2026 buy was BioNTech: 1,015,000 shares worth $94.4M.
  • Logos Global Management added most to Celldex Therapeutics in Q2 2026, an estimated $53.3M increase.
  • Logos Global Management's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $190M.
  • Logos Global Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $84.4M.
  • Logos Global Management's ten largest holdings make up 48% of its $2.32B portfolio in Q2 2026.
  • Logos Global Management opened 25 new positions and closed 23 in Q2 2026.
  • Logos Global Management's portfolio value rose 16% quarter-over-quarter to $2.32B.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.